Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
Thompson LabBiochemistry and Molecular Biotechnology
Morningside Graduate School of Biomedical Sciences
Document Type
Journal ArticlePublication Date
2022-07-01
Metadata
Show full item recordAbstract
During axon degeneration, NAD+ levels are largely controlled by two enzymes: nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) and sterile alpha and toll interleukin motif containing protein 1 (SARM1). NMNAT2, which catalyzes the formation of NAD+ from NMN and ATP, is actively degraded leading to decreased NAD+ levels. SARM1 activity further decreases the concentration of NAD+ by catalyzing its hydrolysis to form nicotinamide and a mixture of ADPR and cADPR. Notably, SARM1 knockout mice show decreased neurodegeneration in animal models of axon degeneration, highlighting the therapeutic potential of targeting this novel NAD+ hydrolase. This review discusses recent advances in the SARM1 field, including SARM1 structure, regulation, and catalysis as well as the identification of the first SARM1 inhibitors.Source
Icso JD, Thompson PR. The chemical biology of NAD+ regulation in axon degeneration. Curr Opin Chem Biol. 2022 Aug;69:102176. doi: 10.1016/j.cbpa.2022.102176. Epub 2022 Jul 1. PMID: 35780654.DOI
10.1016/j.cbpa.2022.102176Permanent Link to this Item
http://hdl.handle.net/20.500.14038/51410PubMed ID
35780654Rights
Copyright © 2022 Elsevier Ltd. All rights reserved.ae974a485f413a2113503eed53cd6c53
10.1016/j.cbpa.2022.102176